Results 121 to 130 of about 721 (165)
Some of the next articles are maybe not open access.
Immunogenicity and safety of glucarpidase for methotrexate toxicity.
Journal of Clinical Oncology, 2014e20648 Background: Glucarpidase converts methotrexate to non-toxic metabolites and is approved for treatment of high-dose methotrexate (HDMTX) induced renal dysfunction.
Brigitte C. Widemann +5 more
openaire +1 more source
Recent Patents on Biotechnology, 2021
Background: Methotrexate (MTX) is a general chemotherapeutic agent utilized to treat a variety of malignancies, woefully, its high doses can cause nephrotoxicity and subsequent defect in the process of MTX excretion. The recombinant form of glucarpidase is produced by engineered E. coli and is a confirmed choice to overcoming this problem. Objective:
Omid Vakili +10 more
openaire +2 more sources
Background: Methotrexate (MTX) is a general chemotherapeutic agent utilized to treat a variety of malignancies, woefully, its high doses can cause nephrotoxicity and subsequent defect in the process of MTX excretion. The recombinant form of glucarpidase is produced by engineered E. coli and is a confirmed choice to overcoming this problem. Objective:
Omid Vakili +10 more
openaire +2 more sources
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity
Journal of Oncology Pharmacy Practice, 2009Purpose. To describe the successful use of glucar- pidase (carboxypeptidase G2) in the treatment of high-dose methotrexate-induced nephrotoxicity in a patient with osteosarcoma. Summary. A 12-year-old female patient who had been diagnosed with low-grade right mandibular osteosarcoma was started on a protocol of cisplatin plus doxorubicin alternating ...
Tuffaha, HW, Al Omar, S
openaire +3 more sources
Methotrexate level discrepancy post‐glucarpidase: A pediatric case series and review of literature
Pediatric Blood & Cancer, 2023AbstractMethotrexate is a common component of pediatric oncology treatment and delayed clearance increases risk of significant toxicities. Glucarpidase is indicated for patients with toxic plasma methotrexate concentrations with renal toxicity. Laboratory interference with immunoassay measurement post‐glucarpidase administration is well established ...
Danielle Kibby, Heidi Trinkman
openaire +2 more sources
Protein Engineering of Glucarpidase to Improve Cancer Therapy Strategies
Qatar Foundation Annual Research Conference Proceedings Volume 2016 Issue 1, 2016Antibody Directed Enzyme Prodrug Therapy (ADEPT) is a technique used in cancer treatment, which convert a prodrug to a powerful cytotoxic drug only in the vicinity of the tumor. The technique relies on a bacterial enzyme, glucarpidase (former name: carboxypeptidase G2, CPG2).
Sayed K Goda +3 more
openaire +1 more source
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
Methotrexate, administered for treatment of pediatric and adult malignancies, is a direct renal toxin, which can lead to renal dysfunction, decreased methotrexate clearance, elevated methotrexate concentrations, and systemic toxicity. Although plasma methotrexate concentrations have been shown to decline precipitously after a single dose of ...
A Mary, Vilay +4 more
openaire +2 more sources
Methotrexate, administered for treatment of pediatric and adult malignancies, is a direct renal toxin, which can lead to renal dysfunction, decreased methotrexate clearance, elevated methotrexate concentrations, and systemic toxicity. Although plasma methotrexate concentrations have been shown to decline precipitously after a single dose of ...
A Mary, Vilay +4 more
openaire +2 more sources
Clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity.
Journal of Clinical Oncology, 20126530 Background: High dose methotrexate (MTX) is used to treat acute lymphoblastic leukemia (ALL), osteogenic sarcoma, non-Hodgkin lymphoma (NHL), and other cancers. MTX-associated renal impairment with delayed MTX elimination develops after 2 to 10% of treatment cycles, exposing patients to elevated MTX concentrations with potential for enhanced MTX
Brigitte C. Widemann +6 more
openaire +1 more source
Insuffisance rénale aiguë après méthotrexate haute-dose : impact de la glucarpidase
Néphrologie & Thérapeutique, 2017Introduction Le methotrexate haute-dose (HD-MTX ≥ 1 g/m2) est utilise pour traiter certaines hemopathies malignes et osteosarcomes. La survenue d’une insuffisance renale aigue (IRA) est une complication classique qui favorise le retard d’elimination du MTX et ses diverses toxicites.
H. Garcia +7 more
openaire +1 more source
Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity.
P & T : a peer-reviewed journal for formulary management, 2014Glucarpidase (Voraxaze) for methotrexate toxicity.
Mohammad A, Rattu +4 more
openaire +1 more source
High-Dose Methotrexate-Induced Renal Dysfunction: Is Glucarpidase Necessary for Rescue?
Journal of Clinical Oncology, 2011TO THEEDITOR: Widemann et al 1 report the use of glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction. When patients develop delayed excretion of methotrexate and impaired renal function after the administration of high-dose methotrexate there are two equally important imperatives.
Paul A. Meyers, Carlos Flombaum
openaire +1 more source